Please login to the form below

Not currently logged in
Email:
Password:

King's profits hit by generic competition

King Pharmaceuticals' second-quarter profit fell 53 per cent to $18m, as generic sales reduced Skelaxin's (metaxalone) revenue by 95 per cent

King Pharmaceuticals' second-quarter profit fell 53 per cent to $18m, or 7 cents per share, from $37.9m or 15 cents per share a year ago as generic sales reduced revenue of its muscle relaxant Skelaxin (metaxalone) by 95 per cent.

Revenue from Skelaxin in the three-month period was just $5m due to the introduction of two unbranded competitors early in the second quarter. A year before it had generated $102m.

Skelaxin came off patent in January 2009 and two companies began selling low-cost generic versions early in the second quarter.

Total branded drug sales in the period ending June 30 reached $162m compared with $275m in the year before. Overall revenue for the second quarter decreased 17 per cent to $371m but exceeded analysts' forecasts of $361m. 

Its pain drug Embeda (morphine sulfate and naltrexone hydrochloride) is showing continued growth since it launched in September 2010 and reaped $15m during the second quarter. But falls in sales were seen with the bleeding-control drug Thrombin-JMI (Thrombin Topical Bovine Origin), Ling's painkiller Avinza (morphine sulfate) and its Flector (diclofenac) painkiller patch.

CEO Brian Markison noted, however, that regulatory filings for both Remoxy (oxycodone) and Acurox (oxycodone HCI/niacin) "remain on track for FDA submission with Remoxy scheduled for the end of this year and Acurox scheduled for the first quarter of 2011."

10th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics